Evaluation of the antiangiogenic potential of AQ4N

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1502-1509

  O'Rourke, Martin ^b   Ward, Claire ^a   Worthington, Jenny ^a   McKenna, Julie ^a   Valentine, Andrea ^b   Robson, Tracy ^b   Hirst, David G ^b   McKeown, Stephanie R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DYNEIN ADENOSINE TRIPHOSPHATASE; FUMAGILLIN; MATRIGEL; PHALLOIDIN; TUBULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN FLAP; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; AORTA; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; COLONIC NEOPLASMS; CYCLOHEXANES; CYTOSKELETON; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, UNSATURATED; HUMANS; LAMININ; MALE; MICE; MICE, INBRED BALB C; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; RATS; RATS, WISTAR; SESQUITERPENES; SKIN; SURGICAL FLAPS; WOUND HEALING;

EID: 40949106780     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1262     Document Type: Article

References (48)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-70.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
4. Isbrucker RA, Cummins J, Pomponi SA, Longley RE, Wright AE. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem Pharmacol 2003;66:75-82.
5. Tan WF, Lin LP, Li MH, et al. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 2003;459:255-62.
6. Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983;221:1185-7.
7. Hong SY, Koh YS, Chung KH, Kim DS. Snake venom disintegrin, saxatilin, inhibits platelet aggregation, human umbilical vein endothelial cell proliferation, and smooth muscle cell migration. Thromb Res 2002;105:79-86.
8. Xiao D, Tan W, Li M, Ding J. Antiangiogenic potential of 10-hydroxycamptothecin. Life Sci 2001;69:1619-28.
9. Stratford IJ, Williams KJ, Cowen RL, Jaffar M. Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin Radiat Oncol 2003;13:42-52.
10. Seddon B, Kelland LR, Workman P. Bioreductive prodrugs for cancer therapy. Methods Mol Med 2004;90:515-42.
11. Nagasawa H, Mikamo N, Nakajima Y, Matsumoto H, Uto Y, Hori H. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1signaling pathway. Anticancer Res 2003;23:4427-34.
12. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 1993;12:119-34.
13. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, Patterson LH. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 1995;72:76-81.
14. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer Suppl 1996;27:S39-42.
15. Friery OP, Gallagher R, Murray MM, et al. Enhancement of the anti-tumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 2000;82:1469-73.
16. Gallagher R, Hughes CM, Murray MM, et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 2001;85:625-9.
17. Iigo M, Shimamura M, Sagawa K, Tsuda H. Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26. Jpn J Cancer Res 1995;86:867-72.
18. Jeong SJ, Higuchi R, Miyamoto T, Ono M, Kuwano M, Mawatari SF. Bryoanthrathiophene, a new antiangiogenic constituent from the bryozoan Watersipora subtorquata (d'orbigny, 1852). J Nat Prod 2002;65:1344-5.
19. Wang XH, Wu SY, Zhen YS. Inhibitory effects of emodin on angiogenesis. Yao Xue Xue Bao 2004;39:254-8.
20. Bertl E, Becker H, Eicher T, et al. Inhibition of endothelial cell functions by novel potential cancer chemopreventive agents. Biochem Biophys Res Commun 2004;325:287-95.
21. Gonzales M, Weksler B, Tsuruta D, et al. Structure and function of a vimentin-associated matrix adhesion in endothelial cells. Mol Biol Cell 2001;12:85-100.
22. Ashton AW, Yokota R, John G, et al. Inhibition of endothelial cellmigration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem 1999;274:35562-70.
23. Suchting S, Heal P, Tahtis K, Stewart LM, Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 2005;19:121-3.
24. Albo D, Wang TN, Tuszynski GP. Antiangiogenic therapy. Curr Pharm Des 2004;10:27-37.
25. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003;42 Suppl 1:S81-91.
26. Miller KD, Sweeney CJ, Sledge GW, Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
27. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 2000;9:1383-96.
28. Hayot C, Farinelle S, De Decker R, et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cellmigration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 2002;21:417-25.
29. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
30. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 1989;58:933-43.
31. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 2000;163:50-9.
32. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990;63:115-22.
33. Kruger EA, Duray PH, Tsokos MG, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 2000;268:183-91.
34. Ruggeri B, Singh J, Gingrich D, et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 2003;63:5978-91.
35. Wittmann T, Waterman-Storer CM. Cell motility: can rho GTPases and microtubules point the way? J Cell Sci 2001;114:3795-803.
36. Yarm F, Sagot I, Pellman D. The social life of actin andmicrotubules: interaction versus cooperation. Curr Opin Microbiol 2001;4:696-702.
37. Verdier-Pinard P, Gares M, Wright M. Differential in vitro association of Vinca alkaloid-induced tubulin spiral filaments into aggregated spirals. Biochem Pharmacol 1999;58:959-71.
38. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
39. Palladini G, Finardi G, Bellomo G. Modifications of vimentin filament architecture and vimentin-nuclear interactions by cholesterol oxides in 73/73 endothelial cells. Exp Cell Res 1996;223:83-90.
40. Chan W, Kozma R, Yasui Y, et al. Vimentin intermediate filament reorganization by Cdc42: involvement of PAK and p70 S6 kinase. Eur J Cell Biol 2002;81:692-701.
41. Helmke BP, Goldman RD, Davies PF. Rapid displacement of vimentin intermediate filaments in living endothelial cells exposed to flow. Circ Res 2000;86:745-52.
42. Bershadsky AD, Vaisberg EA, Vasiliev JM. Pseudopodial activity at the active edge of migrating fibroblast is decreased after drug-induced microtubule depolymerization. Cell Motil Cytoskeleton 1991;19:152-8.
43. Eckes B, Colucci-Guyon E, Smola H, et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 2000;113:2455-62.
44. Palazzo AF, Joseph HL, Chen YJ, et al. Cdc42, dynein, and dynactin regulate MTOC reorientation independent of rho-regulated microtubule stabilization. Curr Biol 2001;11:1536-41.
45. Hestermann A, Rehberg M, Graf R. Centrosomal microtubule plus end tracking proteins and their role in dictyostelium cell dynamics. J Muscle Res Cell Motil 2002;23:621-30.
46. Helfand BT, Mikami A, Vallee RB, Goldman RD. A requirement for cytoplasmic dynein and dynactin in intermediate filament network assembly and organization. J Cell Biol 2002;157:795-806.
47. Cramer LP, Siebert M, Mitchison TJ. Identification of novel graded polarity actin filament bundles in locomoting heart fibroblasts: implications for the generation of motile force. J Cell Biol 1997;136:1287-305.
48. Fenteany G, Zhu S. Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem 2003;3:593-616.